Golvatinib

DB11977InvestigationalSmall molecule

Golvatinib has been investigated for the treatment of Platinum-Resistant Squamous Cell Carcinoma of the Head and Neck.

Mechanism: Pharmacologically active on Hepatocyte growth factor receptor and Vascular endothelial growth factor receptor 2
Curator reviewed
Formula / weight: C₃₃H₃₇F₂N₇O₄ · 633.701 g/mol (avg)
Code names: E-7050

Resolves to

Compound

Structure

InChIKeyUQRCJCNVNUFYDX-UHFFFAOYSA-NSMILESCN1CCN(CC1)C1CCN(CC1)C(=O)NC1=CC(OC2=CC=C(NC(=O)C3(CC3)C(=O)NC3=CC=C(F)C=C3)C(F)=C2)=CC=N1

Targets

What you can answer from here — as of August 30, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

7Clinical trialsPhase, status and sponsor resolved per trial

12+ReferencesStructured and connected to the statements they support

Which drugs share a target with Golvatinib, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.